Table V.
Summary matrix for ICSI patient samples (Quinn's Advantage® Medium with HEPES) treated with selected compound(s).
| Sample ID | WHO category | #1 |
#26 |
#30 |
#36 |
#37 |
#38 |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TM | PM | TM | PM | TM | PM | TM | PM | TM | PM | TM | PM | ||
| Decreasing total motility | |||||||||||||
| 1160 | WHO normal | ― | ― | ― | ― | ↓ | ↑ | ||||||
| 1163 | WHO normal | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||||
| 1213 | WHO normal | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||||||
| 1251 | WHO normal | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||||||
| 1309 | WHO normal | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||
| 873 | WHO normal | ― | ― | ↑ | ↑ | ― | ― | ― | ― | ― | ― | ― | ― |
| 1154 | Borderline | ↑ | ↑ | ― | ↑ | ↑ | ↑ | ↑ | ↑ | ||||
| 1236 | Borderline | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||
| 1233 | Borderline | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||
| 1162 | Borderline | ― | ↑ | ― | ↑ | ― | ↑ | ― | ↑ | ||||
| 1150 | Low TM and PM | ↑ | ↑ | ― | ― | ― | ↑ | ↑ | ― | ||||
| 1183 | Low TM and PM | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||||||
| 1038 | Low TM and PM | ↑ | ↑ | ↑ | ↑ | ||||||||
| 1261 | Low TM and PM | ↑ | ↑ | ↑ | ↑ | ||||||||
| 1301 | Low TM and PM | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||||||
| 1257 | Low TM and PM | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||||
↑, Significant increase; ― no change; ↓, significant decrease; empty cell, drug was not used in the experiment.
WHO normal: WHO normal limits for total motility (40%) and progressive motility (32%), borderline: borderline motility, low TM and low PM: both total and progressive motility are below the WHO normal limit. No entry means compound is not tested. Significance means SD do not overlap (TM: total motility, PM: progressive motility).